Update on Pharmacoeconomics in the Irish Healthcare Setting, 15th & 16th May 2019 in Dublin Castle.
Online access to slides please click here
Health Technology Assessment (HTA) of population-based colorectal cancer screening programme in Ireland
This HTA was prepared by the National Cancer Registry Ireland, the National Centre for Pharmacoeconomics, the School for Health & Related Research, Sheffield University and Dublin City University. It is available on the HIQA website.
The NCPE are currently recruiting for a Health Technology Assessor (Permanent, Full Time & Pensionable).
The closing date for applications is 9th April 2023.
Further details and application form are available here.
Enquiries to Dr Lesley Tilson ([email protected] ) or Prof Michael Barry ([email protected] )
The Beneluxa collaboration has issued a joint statement with the Nordic Pharmaceutical Forum. The statement reiterates the importance of cost effectiveness in the assessment of value for medicines as well as the challenges with the lack of availability of robust clinical evidence for decision makers in a timely manner. Joint working on these problems is at the heart of this collaboration.
Joint statement Beneluxa and NPF
Lixisenatide (Lyxumia®) for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
||Full Pharmacoeconomic Evaluation Recommended
||Reimbursement not Recommended
The NCPE does not recommend reimbursement of lixisenatide for patients with type 2 diabetes mellitus at the submitted price.
Notice for Applicants:
Please refer to updated versions of the Guidelines for Inclusion of Drug Costs v3.1, Applicant submission template v2. and the Budget Impact Model Template v1.5 when making submissions.
Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations v3.1
Applicant Template v2.1
Budget Impact Model Template v1.5
Cost-effectiveness of Oncotype DX® to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland.
||Reimbursement not recommended at the submitted price
3rd October 2011
Following a price revision the NCPE now consider Oncotype DX a cost-effective therapy to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positve, early stage breast cancer in Ireland.
Oncotype DX summary
The HSE has approved reimbursement following confidential price negotiations.
The NCPE are delighted to facilitate the delivery of the HTA module of the IPPOSI Pilot Patient Education Programme, commencing this Monday 22nd January. This module will provide students with a detailed knowledge of the principals of HTA, and has been adapted by the NCPE to provide particular insight into the practice of HTA in the Irish setting. Delivery of this module is part of the NCPE’s wider initiative to collaborate with patient groups during the HTA process.’
Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland
PCV13 is the most cost-effective option if the analysis is based on a serotype distribution reflecting 2011 data.
Professor Michael Barry, Director of the National Centre for Pharmacoeconomics joins the inaugural Heads of Agency Group
Press Release HAG EUNETHTA21 Final Version 202110086
Cost effectiveness analysis of a universal infant rotavirus vaccination programme in Ireland.
In January 2010, the National Centre for Pharmacoeconomics completed the evaluation of the cost-effectiveness of a universal rotavirus vaccination programme in Ireland, on behalf of the National Immunisation Advisory Committee (NIAC). A summary of the main findings are available in the attached document.
Rotavirus Vaccine summary
The 9th Annual SPHeRE Network Conference is due to be held Thursday 23rd March in the Royal College of Surgeons, Ireland (RCSI).
NCPE staff members will attend and present NCPE research at the SPHeRE conference.
- Dr Aine Varley will give an oral presentation at 11am in room TR3 (Health Services Research I parallel session).
The title of the presentation is:
‘A retrospective analysis of HTA outcomes for antimicrobial drugs in Ireland’
- Dr Caroline Walsh will present a poster titled:
‘Identification of the Challenges an Potential Solutions Associated with the Use of Basket Trials in the Health Technology Assessment of Drugs’
Further details on the SPHeRE Annual Conference can be found here
Cost effectiveness analysis of a universal infant hepatitis B vaccination programme in Ireland
In October 2006, the National Centre for Pharmacoeconomics conducted an economic evaluation of the cost-effectiveness of a universal hepatitis B vaccination programme, for the Health Protection Surveillance Centre/National Immunisation Advisory Committee. A summary of the main findings are available in the attached document.
Universal Infant Hepatitis B Vaccine Programme summary
Given the ongoing Covid-19 outbreak , the NCPE Annual Symposium “Update on Pharmacoeconomics in the Irish Healthcare Setting” is being postponed until later this year.
Further enquiries should be sent to [email protected]
Version 3.0 of the Full HTA Submission Template is available here. This template, to be completed by Applicants, outlines the content and format of the written submission to the NCPE as part of a full HTA. For those companies who have already started to prepare a full HTA submission, the previous version of the template (Version 2.1) will be acceptable until 01 July 2023.
Notice to Applicants: Please refer to updated versions of the RR Submission Template v2.2, Applicant Template v2.1, and the Submission Checklist v1.4 when making submissions. These are available from the Submission Templates section of the website.
This template, to be completed by Applicants, is intended to provide a summary of information to facilitate the rapid review process. Version 2.1 of this template was published on 07 April 2022 and replaces version 2.0. Submissions using the old template (version 2.0) will be accepted until 12 May 2022, after which time only submissions using v 2.1 will be accepted. Version 2.1 includes a requirement to submit the NCPE Budget Impact Model Template for all Rapid Review submissions. Further information may be requested from the NCPE if necessary. Please email [email protected].
RR Submission template v 2.1